Medicilon Assists Huaota's CD73-targeting ADC approved for clinical use in US

Recently, Shanghai Huaota Biopharmaceutical Co., Ltd. (Huaota) received a notification from the US FDA, agreeing that the third-generation antibody drug conjugate (ADC) project HB0052 developed by the company targeting the CD73 antigen will enter clinical trials.  This is the first antibody conjugate drug project approved by Huaota Biotech to enter clinical trials by the FDA.

As a partner of Huaota, Shanghai Medicilon Inc. (Medicilon) relied on its antibody drug conjugate R&D service platform and its professional technical capabilities and rich project experience to provide HB0052 with R&D of the drug metabolism and safety evaluation tests that complied with GLP standards to ensure high-quality and efficient advancement.

Medicilon Antibody Drug Conjugate R&D Service Platform 

Pressing the "Accelerator Button" for ADC Drug Development

As one of the rare one-stop biopharmaceutical preclinical R&D service platforms in China, Medicilon has established an antibody drug conjugate (ADC) R&D service platform.  Through continuous technological innovation, Medicilon could provide clients with one-stop preclinical research services such as ADC Payloads synthesis, ADC drug conjugation, ADC pharmacodynamics evaluation, ADC pharmacokinetics evaluation and ADC safety evaluation.

Since its establishment, the Medicilon Antibody Drug Conjugate (ADC) R&D service platform has reached many years of continuous collaboration with a lot of clients such as Bio-Thera Solutions, DAC Biotech, and Xuanzhu Biopharmaceutical.  As of May 2023, Medicilon has successfully helped 17 ADC drugs obtain clinical approval, and there are multiple ongoing ADC projects currently.

About Huaota

Huaota Biopharmaceutical is a new biological drug R&D enterprise focusing on independent development and focusing on the world.  Focusing on the research and development of new biological drugs in the fields of tumors, autoimmune diseases, and fundus lesions, there are currently 11 projects in the clinical stage: including the first Chinese developed IL-36R monoclonal antibody for pustular psoriasis (rare disease) that is about to enter the critical phase II; the PD-L1/VEGF dual antibody has been in clinical phase II and has observed positive signals in endometrial cancer and renal cancer; and core projects such as the first CD73-ADC with dual killing effect targeting refractory tumors such as pancreatic cancer.

Huaota Biopharmaceutical is currently actively looking for domestic and foreign partners to jointly promote and develop, and looks forward to providing high-quality and high-level biopharmaceuticals to the global market to meet the needs of patients for biopharmaceuticals with high accessibility and affordability, and implement the vision of innovation to change the world!

About Medicilon

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  By the end of June 2023, Medicilon has provided new drug R&D services to more than 2,000 clients around the world, and participated in the R&D of 385 new drug projects that have been approved for clinical trials.  Medicilon is proud to contribute to human health in the globe.